The OCLNGene and Protein
The OCLNgene (OMIM *602876) is located on chromosome 5q13.2 and encodes occludin, a ~65-kDa integral membrane protein that is a core structural component of the tight junction complex. Tight junctions seal the spaces between adjacent endothelial and epithelial cells and are essential for maintaining the blood-brain barrier. Occludin contains two main functional domains: an N-terminal MARVEL domain (encoded mainly by exons 3 and 4), which mediates membrane apposition, and a C-terminal OCLN/ELL domain involved in cytokine-induced regulation of the tight junction barrier.
A Technically Challenging Gene to Sequence
OCLN analysis is complicated by a highly homologous pseudogene located ~1.5 Mb upstream within a large inverted duplication, sharing ~99.75% sequence identity with exons 5–9 of the real gene. The copy number of this duplicated region varies between individuals (2 to >5 copies). As a result, a combination of techniques (copy number analysis, MLPA, targeted long-range PCR, and in some cases cDNA sequencing from lymphoblastoid cell lines) has been required to reliably identify mutations, particularly in exons 5–9.
Type of Mutations
Reported pathogenic variants in OCLNare diverse and include:
• Large intragenic deletions, most notably one removing the entire MARVEL domain (exons 3–4)
• Frameshift variants
• Nonsense (stop-gain) variants
• Splice-site variants
• A complex genomic rearrangement in which the pseudogene recombines into exon 9
• Missense variants (less common)
Mutational Spectrum: High Allelic Heterogeneity, with One Notable Exception
Unlike some recessive neurodevelopmental genes where a single ancestral mutation accounts for most cases, OCLNshows considerable allelic heterogeneity; overall, different families tend to carry their own private mutations, scattered across exons 3, 4, 6, and 9.
That said, one specific deletion stands out: the deletion removing the transmembrane domain spanning exons 3 and 4 (c.51-?730-?del, p.Lys18_Glu243) was originally described by O’Driscoll et al. (2010) and was subsequently found again by Abdel-Hamid, Abdel-Salam, Zaki et al. (2017) in 5 of 10 unrelated Egyptian families (50%)— the largest single cohort reported to date. The authors explicitly raised this as evidence of a founder mutation in the Egyptian population. Whether this represents a single shared ancestral haplotype or a recurrent mutational hotspot has not yet been formally tested with haplotype analysis, but its high frequency in this cohort is clinically useful: it may be reasonable to test for this specific deletion as a first step in Egyptian patients with a compatible phenotype.
A separate frameshift variant identified in Turkish families has also been reported in more than one unrelated family and has been specifically associated with renal failure, raising the question of a possible second founder effect or mutational hotspot in that population, though this has not been formally confirmed.
Pathophysiologic Mechanism
Loss of functional occludin compromises tight junction integrity in cerebral blood vessels. Because tight junctions in the brain are functional from early fetal life, their disruption is thought to allow vascular leakage and an abnormal local inflammatory/ischemic environment in the developing cortex (consistent with the vascular-associated calcification pattern and the polymicrogyria). Neuropathological examination of at least one affected individual showed similarities to the Ocln knockout mouse model, in which calcification is predominantly associated with blood vessels.
This structural, vascular-integrity mechanism is fundamentally different from the interferon-driven inflammatory mechanism underlying Pseudo-TORCH Syndromes 2 and 3, even though all three conditions can present with a broadly similar clinical picture.
Diagnostic Testing
• Whole exome sequencing (WES) or targeted neurodevelopmental gene panels are commonly used as an initial diagnostic approach, since several reported patients were identified this way. However, given the pseudogene complication described above, a positive or negative WES result for OCLN should be interpreted with caution, and confirmatory testing is recommended for a definitive diagnosis.
• Targeted OCLNsequencing combined with copy number analysis is recommended, given the pseudogene interference
• MLPA or targeted deletion/duplication analysis should be considered, especially for the exon 3–4 deletion
• In Egyptian patients, targeted testing for the exon 3–4 deletion (c.51-?_730-?del) may be a reasonable first-line test
• Where standard approaches are inconclusive, cDNA analysis from lymphoblastoid cell lines has been used in research settings
[Figure 3: Schematic of occludin within the tight junction complex, the OCLN gene/pseudogene architecture on 5q13.2, and the recurrent exon 3–4 deletion]
